Latest news with #IDEXXLaboratories
Yahoo
3 days ago
- Business
- Yahoo
Piper Sandler Raises IDEXX Laboratories (IDXX) PT to $700, Cites Strong Q2 Results
IDEXX Laboratories Inc. (NASDAQ:IDXX) is one of the best performing S&P 500 stocks to buy now. On August 11, Piper Sandler raised the firm's price target on Idexx Laboratories to $700 from $510 following the company's Q2 2025 financial results. The firm kept a Neutral rating on the shares. IDEXX Laboratories reported total revenues of $1,109 million in Q2, which was an increase of 11% as reported and 9% organically, compared to the prior year. This was driven by a strong performance from its Companion Animal Group/CAG and Water segments, which saw revenue increases of 11% and 9% as reported, respectively. A veterinarian in a veterinary clinic examining a companion animal. Within the Companion Animal Group, IDEXX VetLab consumables revenue grew by 15% as reported and 14% organically. The company also saw a 66% reported increase in CAG Diagnostics capital instrument revenues, driven by record placements of its new IDEXX InVue Dx instrument. Rapid assay products revenues, however, declined by 3% as both reported and organic, as some testing shifted to new modalities. IDEXX Laboratories Inc. (NASDAQ:IDXX) develops, manufactures, and distributes products for the companion animal veterinary, livestock and poultry, dairy, and water testing industries in the US and internationally. While we acknowledge the potential of IDXX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
08-08-2025
- Business
- Yahoo
Al Gore's Generation Investment Management Reduces Amazon.com Inc by 3.8% in Q2 2025
Exploring the Strategic Moves of a Sustainability-Focused Investment Firm Introduction to Al Gore (Trades, Portfolio) and Generation Investment Management Warning! GuruFocus has detected 7 Warning Sign with MSFT. Al Gore (Trades, Portfolio), the former Vice President of the United States, is renowned for his environmental advocacy and commitment to sustainable development. In 2004, he co-founded Generation Investment Management alongside David Blood. This London-based firm is dedicated to long-term investing with a focus on sustainability, integrating economic, social, and environmental considerations into its investment strategies. Generation Investment Management serves a diverse clientele, including pooled investment vehicles and pension plans, and offers a range of products such as Global Equity and Climate Solutions. The firm emphasizes a systematic approach to global challenges, identifying key drivers of change like climate change and resource scarcity, which can significantly impact a company's performance. Summary of New Buy Al Gore (Trades, Portfolio) added a total of three stocks to his portfolio in the second quarter of 2025. The most significant addition was IDEXX Laboratories Inc (NASDAQ:IDXX), with 567,322 shares, accounting for 1.93% of the portfolio and a total value of $304.28 million. The second largest addition was West Pharmaceutical Services Inc (NYSE:WST), consisting of 1,165,777 shares, representing approximately 1.62% of the portfolio, with a total value of $255.07 million. The third largest addition was Moody's Corp (NYSE:MCO), with 271,074 shares, accounting for 0.86% of the portfolio and a total value of $135.97 million. Key Position Increases Al Gore (Trades, Portfolio) also increased stakes in a total of seven stocks. The most notable increase was in Danaher Corp (NYSE:DHR), with an additional 1,787,522 shares, bringing the total to 4,965,646 shares. This adjustment represents a significant 56.24% increase in share count, a 2.25% impact on the current portfolio, with a total value of $980.91 million. The second largest increase was in Visa Inc (NYSE:V), with an additional 660,362 shares, bringing the total to 1,373,485. This adjustment represents a significant 92.6% increase in share count, with a total value of $487.66 million. Summary of Sold Out Al Gore (Trades, Portfolio) completely exited four holdings in the second quarter of 2025. Notably, he sold all 635,999 shares of Mastercard Inc (NYSE:MA), resulting in a -2.11% impact on the portfolio. Additionally, he liquidated all 755,325 shares of Waters Corp (NYSE:WAT), causing a -1.68% impact on the portfolio. Key Position Reduces Al Gore (Trades, Portfolio) also reduced positions in 23 stocks. The most significant change was a reduction in Inc (NASDAQ:AMZN) by 3,309,515 shares, resulting in a -65.77% decrease in shares and a -3.8% impact on the portfolio. The stock traded at an average price of $197.77 during the quarter and has returned 18.24% over the past three months and 1.70% year-to-date. Another notable reduction was in Becton Dickinson & Co (NYSE:BDX) by 2,537,140 shares, resulting in a -47.9% reduction in shares and a -3.51% impact on the portfolio. The stock traded at an average price of $184.01 during the quarter and has returned 12.97% over the past three months and -16.40% year-to-date. Portfolio Overview As of the second quarter of 2025, Al Gore (Trades, Portfolio)'s portfolio included 37 stocks. The top holdings were 15.93% in Microsoft Corp (NASDAQ:MSFT), 8.05% in Charles Schwab Corp (NYSE:SCHW), 7.65% in MercadoLibre Inc (NASDAQ:MELI), 6.24% in Danaher Corp (NYSE:DHR), and 4.84% in Steris PLC (NYSE:STE). The holdings are mainly concentrated in seven of the 11 industries: Technology, Healthcare, Consumer Cyclical, Financial Services, Industrials, Communication Services, and Real Estate. This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
06-08-2025
- Business
- Yahoo
Why a Company You've Never Heard of Is One of the Best Nasdaq-100 Stocks of the Year
Occupying the runner-up spot behind retail darling Palantir (PLTR) in the race for the best-performing stocks in the Nasdaq-100 ($IUXX) is no easy feat. This means one has to outperform giants such as Nvidia (NVDA), Microsoft (MSFT), and Meta (META). With a YTD rally of 59.4%, shares of IDEXX Laboratories (IDXX) have done this quite comfortably. About IDEXX Laboratories Founded in 1983, IDEXX Laboratories is a vet tech company that develops, manufactures, and distributes diagnostic and software solutions for companion animals, livestock, and water testing markets. With constant innovation, led by its SNAP tests and cellular analyzers, the company has become the global leader in veterinary diagnostics, software, and water testing. More News from Barchart Palantir's Free Cash Flow Margins and Forecasts Rise - Where This Leaves PLTR Stock Cathie Wood is Buying Figma Stock with Both Hands. Should You Buy This Hot IPO, Too? Can SoundHound's Q2 Results Send the Stock Soaring on August 7? Get exclusive insights with the FREE Barchart Brief newsletter. Subscribe now for quick, incisive midday market analysis you won't find anywhere else. The company's market cap currently stands at $54.9 billion. At the start of the year, it was around $34 billion. So why are investors so hot on IDEXX right now? Let's find out! Blockbuster Q2 Results One of the primary reasons for the outperformance in IDEXX's share price has been its recent solid quarterly results. The company has reported an earnings beat in each of the past four quarters. In Q2 2025, IDEXX reported revenues of $1.1 billion, which marked yearly growth of 11%. The Companion Animal Group or CAG, the largest business segment of the company, generated 10% organic revenue growth. Within that, the IDEXX VetLab consumables segment reported 14% organic revenue growth. Overall, product and service revenues came in at $657.6 million and $451.9 million, up from $577.3 million and $426.3 million in the prior year, respectively. Meanwhile, earnings surged by 49% in the same period to $3.63 per share, coming in ahead of the consensus estimate of $3.30 per share. Notably, gross and operating margins improved as well to 62.6% and 33.6% compared to 61.7% and 26.3%, respectively. However, for the six months ended June 30, 2025, net cash from operating activities came down to $423.7 million from $446.9 million in the year-ago period. Overall, the company closed the quarter with a cash balance of $164.6 million, higher than its short-term debt levels of $75 million. Encouragingly, IDEXX raised its revenue guidance for the year to between $4.21 billion and $4.28 billion from between $4.09 billion and $4.21 billion earlier, coupled with a rise in the EPS range to $12.40-$12.76, up from $11.93-$12.43 previously. IDEXX Has a Competitive Edge But Creates Valuation Concerns IDEXX Laboratories stands out for its consistently strong financial footing, largely driven by the dependable nature of its recurring revenues and long-term client relationships. Its strategy of focusing on consumable products with high margins has not only bolstered earnings, but also ensured stability across economic cycles. Over the years, IDEXX has developed a comprehensive diagnostic infrastructure for veterinary use, giving it a clear strategic lead. A critical element within this ecosystem is the CLIP cartridge or Chemistry Liquid In-Pack. These are preassembled panels of dry chemistry slides, tailored to conduct specific blood tests such as those related to liver health, kidney function, or broader wellness metrics. These CLIPs are loaded into the Catalyst One device, an analyzer widely used in veterinary practices for in-house blood testing. Catalyst One enables clinics to run tests on-site and receive results within 10-15 minutes, streamlining the diagnostic process. Once the analysis is complete, data is both displayed on-screen and automatically transferred to the IDEXX VetLab Station. This central interface coordinates information from all connected instruments in the clinic. Its touchscreen display and software integration reduce manual steps and help prevent data handling errors. Monthly calibration using the SmartQC solution, developed by IDEXX, is required to maintain precise results. Meanwhile, IDEXX has introduced two notable offerings that can be significant future growth drivers. One is the inVue Dx cellular analyzer, which uses AI-driven tools to automate several routine lab tasks. This system has seen strong initial adoption with 2,400 units being placed in the second quarter of 2025. The other is the Cancer Dx panel, a diagnostic test capable of detecting canine lymphoma from a blood sample. Within a month of launch, over a thousand clinics had already placed orders, reflecting high demand. Future plans include a steady expansion of IDEXX's diagnostic toolkit. The company intends to roll out additional cancer-related tests and extend the functionality of inVue Dx to support fine needle aspirate procedures. These steps are expected to enhance the depth and frequency of diagnostics conducted during pet visits, contributing to higher adoption of IDEXX solutions across veterinary practices. However, amid all this optimism, the stock is trading at punchy valuations and a significant premium to the industry average. Its forward price-earnings, price-sales, and price-cash flow at 43.86x, 10.38x, and 37.07x are all considerably higher than the sector medians of 16.87x, 3.45x, and 13.76x, respectively. Analyst Opinions on IDXX Stock Taking all of this into account, analysts have rated IDEXX stock a 'Moderate Buy' with a mean target price and high target price of $558.30 and $626, respectively. Both has been surpassed in another nod to the significant share price rally. Out of 11 analysts covering the stock, six have a 'Strong Buy' rating, one has a 'Moderate Buy' rating, and four have a 'Hold' rating. On the date of publication, Pathikrit Bose did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on
Yahoo
04-08-2025
- Business
- Yahoo
S&P 500 Gains and Losses Today: Retail Sector Stocks Rise Amid Rate Cut Hopes
Key Takeaways The S&P 500 jumped 1.5% on Monday, Aug. 4, 2025, snapping a four-day losing streak as stocks bounced back from the previous session's sell-off. Growing expectations that the Fed will move to lower interest rates, which would lower the cost of borrowing for consumers, helped underpin gains for various retail stocks. IDEXX Laboratories beat quarterly estimates and raised its full-year forecasts, and shares of the animal healthcare company skyrocketed to lead S&P 500 gainers. Shares of ON Semiconductor tumbled after the chipmaker discussed cautious spending by its customers and uncertainty in the automotive U.S. equities indexes pushed higher at the top of the new trading week, bouncing back from declines posted ahead of the weekend. Although weaker-than-expected jobs data released on Friday raised concerns about the resilience of the economy, the slowdown in hiring and uptick in unemployment could add to the case for upcoming interest-rate cuts by the Federal Reserve. The S&P 500 gained 1.5% on Monday, ending a streak of four consecutive negative trading sessions. The Dow also clawed back from Friday's sell-off, adding 1.3%, while the Nasdaq climbed around 2%. Shares of animal health company IDEXX Laboratories (IDXX) secured the top performance in the S&P 500 on Monday with a surge of more than 27%. The provider of diagnostics tools and other equipment for veterinary laboratories topped sales and profit estimates for the second quarter and lifted its full-year forecasts, citing strong demand for a recently launched product that analyzes samples from animals' ears. William Blair analysts said IDEXX could also benefit from an aging pet population driven by accelerated pet adoptions during the pandemic. Growing expectations that the Fed will move to lower interest rates, which would lower the cost of borrowing for consumers, helped underpin gains for various retail stocks. Shares of kitchenware and home furnishings specialist Williams-Sonoma (WSM) jumped 6.9%. Shares of Tapestry (TPR), the fashion holding company behind the Kate Spade and Coach brands, advanced 5.3%. PG&E (PCG) shares gained 6.5%, recovering from losses posted late last week after the California-based power utility reported a year-over-year revenue decline for the second quarter, falling short of expectations. However, CEO Patricia Poppe said the energy provider could be in a position to reduce customer bills within the next couple of years as it executes its growth plans. PG&E also said it does not intend to issue additional equity to fund its spending plans, regardless of the outcome on potential state legislation on wildfire prevention and customer billing that could affect utilities in the Golden State. Shares of analog and power management chipmaker ON Semiconductor (ON) fell the furthest of any S&P 500 stock on Monday, plummeting nearly 16%. Although Onsemi matched adjusted profit estimates and edged ahead of quarterly sales expectations, revenue was down from a year ago. The company pointed to cautious behavior by its customers, high levels of uncertainty in its key automotive market, and softness in Europe and North America. Paramount Global (PARA) announced that David Ellison will take the reins of the combined company following the completion of the merger later this week between Paramount and Ellison's Skydance Media. Meanwhile, Tom Ryan is set to step down from his role as president and CEO of Paramount Streaming. Paramount Global shares tumbled 5.4% on Monday. LyondellBasell Industries (LYB) shares dropped 4.7%, extending losses posted Friday after the producer of plastics, chemicals, and fuels reported lower-than-expected profits for the second quarter. Although revenue came in ahead of expectations, LyondellBasell outlined a strategic plan including asset sales in an effort to optimize its portfolio in response to challenging market conditions. Read the original article on Investopedia Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
04-08-2025
- Business
- Yahoo
IDEXX Laboratories Stock Jumps as Pet Health Care Firm Lifts Full-Year Outlook
Shares of IDEXX Laboratories (IDXX) soared more than 10% in premarket trading Monday after the pet health care company reported better-than-expected second-quarter results and raised its 2025 profit and revenue forecasts. The Westbrook, Maine-based firm posted GAAP earnings per share of $3.63 on revenue that increased 11% year-over-year to $1.11 billion. Analysts surveyed by Visible Alpha had expected $3.30 and $1.06 billion, respectively. IDEXX lifted its full-year EPS projection to a range of $12.40 to $12.76 from the prior $11.93 to $12.43. It also raised its revenue outlook to $4.205 billion to $4.280 billion from $4.095 billion to $4.210 billion. "Our focus on helping veterinarians gain deeper diagnostic insights to inform patient care continues to drive customer loyalty and sets a solid foundation for sustained long-term growth," IDEXX CEO Jay Mazelsky said. IDEXX Laboratories shares entered the day up nearly 30% in 2025. Read the original article on Investopedia
